Eur Heart J:癌症患者的心血管疾病风险明显更高

2019-12-30 不详 MedSci原创

本次观察性研究的目的旨在评估多个癌症中心患者的心血管疾病(CVD)死亡风险。本研究对正常人群和3234256名美国癌症幸存者(1973-2012年)进行了监测、流行病学和最终结果的比较。在28个癌症种类患者中,有1228328名患者(38%)死于癌症,365689名患者(11.3%)死于CVD。在死于CVD的患者中,有76.3%的患者是死于心脏病。在八个癌症中心,心血管疾病的死亡率风险在至少一个日

本次观察性研究的目的旨在评估多个癌症中心患者的心血管疾病(CVD)死亡风险。

本研究对正常人群和3234256名美国癌症幸存者(1973-2012年)进行了监测、流行病学和最终结果的比较。在28个癌症种类患者中,有1228328名患者(38%)死于癌症,365689名患者(11.3%)死于CVD。在死于CVD的患者中,有76.3%的患者是死于心脏病。在八个癌症中心,心血管疾病的死亡率风险在至少一个日历年内超过了癌症死亡率风险指数。心血管死亡风险在诊断癌症年龄<35岁的患者中最高。另外,心血管死亡风险在诊断癌症后1年内最高,且在随访期间CVD的风险较正常人群一直处于高水平。

研究结果显示,在癌症患者中,心血管疾病风险最高的癌症是乳腺癌、前列腺癌和膀胱癌。与正常人群相比,癌症患者的心血管风险始终处于较高水平。

原始出处:

本文系梅斯医学(MedSci)原创编译整理,转载需授权


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1289661, encodeId=5f691289661b9, content=<a href='/topic/show?id=cbb8e1356f7' target=_blank style='color:#2F92EE;'>#癌症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71356, encryptionId=cbb8e1356f7, topicName=癌症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ba218, createdName=zgwhgch, createdTime=Wed Jan 01 01:24:00 CST 2020, time=2020-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357348, encodeId=9aa0135e34809, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Jan 01 01:24:00 CST 2020, time=2020-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473218, encodeId=a16214e32184b, content=<a href='/topic/show?id=862be0746bc' target=_blank style='color:#2F92EE;'>#疾病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70746, encryptionId=862be0746bc, topicName=疾病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c757221906, createdName=花花1368, createdTime=Wed Jan 01 01:24:00 CST 2020, time=2020-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498674, encodeId=5fc314986e42c, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Wed Jan 01 01:24:00 CST 2020, time=2020-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563195, encodeId=e0291563195c0, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Wed Jan 01 01:24:00 CST 2020, time=2020-01-01, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1289661, encodeId=5f691289661b9, content=<a href='/topic/show?id=cbb8e1356f7' target=_blank style='color:#2F92EE;'>#癌症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71356, encryptionId=cbb8e1356f7, topicName=癌症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ba218, createdName=zgwhgch, createdTime=Wed Jan 01 01:24:00 CST 2020, time=2020-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357348, encodeId=9aa0135e34809, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Jan 01 01:24:00 CST 2020, time=2020-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473218, encodeId=a16214e32184b, content=<a href='/topic/show?id=862be0746bc' target=_blank style='color:#2F92EE;'>#疾病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70746, encryptionId=862be0746bc, topicName=疾病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c757221906, createdName=花花1368, createdTime=Wed Jan 01 01:24:00 CST 2020, time=2020-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498674, encodeId=5fc314986e42c, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Wed Jan 01 01:24:00 CST 2020, time=2020-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563195, encodeId=e0291563195c0, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Wed Jan 01 01:24:00 CST 2020, time=2020-01-01, status=1, ipAttribution=)]
    2020-01-01 zhaojie88
  3. [GetPortalCommentsPageByObjectIdResponse(id=1289661, encodeId=5f691289661b9, content=<a href='/topic/show?id=cbb8e1356f7' target=_blank style='color:#2F92EE;'>#癌症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71356, encryptionId=cbb8e1356f7, topicName=癌症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ba218, createdName=zgwhgch, createdTime=Wed Jan 01 01:24:00 CST 2020, time=2020-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357348, encodeId=9aa0135e34809, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Jan 01 01:24:00 CST 2020, time=2020-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473218, encodeId=a16214e32184b, content=<a href='/topic/show?id=862be0746bc' target=_blank style='color:#2F92EE;'>#疾病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70746, encryptionId=862be0746bc, topicName=疾病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c757221906, createdName=花花1368, createdTime=Wed Jan 01 01:24:00 CST 2020, time=2020-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498674, encodeId=5fc314986e42c, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Wed Jan 01 01:24:00 CST 2020, time=2020-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563195, encodeId=e0291563195c0, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Wed Jan 01 01:24:00 CST 2020, time=2020-01-01, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1289661, encodeId=5f691289661b9, content=<a href='/topic/show?id=cbb8e1356f7' target=_blank style='color:#2F92EE;'>#癌症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71356, encryptionId=cbb8e1356f7, topicName=癌症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ba218, createdName=zgwhgch, createdTime=Wed Jan 01 01:24:00 CST 2020, time=2020-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357348, encodeId=9aa0135e34809, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Jan 01 01:24:00 CST 2020, time=2020-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473218, encodeId=a16214e32184b, content=<a href='/topic/show?id=862be0746bc' target=_blank style='color:#2F92EE;'>#疾病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70746, encryptionId=862be0746bc, topicName=疾病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c757221906, createdName=花花1368, createdTime=Wed Jan 01 01:24:00 CST 2020, time=2020-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498674, encodeId=5fc314986e42c, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Wed Jan 01 01:24:00 CST 2020, time=2020-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563195, encodeId=e0291563195c0, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Wed Jan 01 01:24:00 CST 2020, time=2020-01-01, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1289661, encodeId=5f691289661b9, content=<a href='/topic/show?id=cbb8e1356f7' target=_blank style='color:#2F92EE;'>#癌症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71356, encryptionId=cbb8e1356f7, topicName=癌症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ba218, createdName=zgwhgch, createdTime=Wed Jan 01 01:24:00 CST 2020, time=2020-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357348, encodeId=9aa0135e34809, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Jan 01 01:24:00 CST 2020, time=2020-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473218, encodeId=a16214e32184b, content=<a href='/topic/show?id=862be0746bc' target=_blank style='color:#2F92EE;'>#疾病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70746, encryptionId=862be0746bc, topicName=疾病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c757221906, createdName=花花1368, createdTime=Wed Jan 01 01:24:00 CST 2020, time=2020-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498674, encodeId=5fc314986e42c, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Wed Jan 01 01:24:00 CST 2020, time=2020-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563195, encodeId=e0291563195c0, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Wed Jan 01 01:24:00 CST 2020, time=2020-01-01, status=1, ipAttribution=)]
    2020-01-01 slcumt

相关资讯

Heart:男性与更大的胸主动脉直径呈独立相关

本研究的目的旨在提供55岁或55岁以上男性和女性胸主动脉直径的人群分布,并确定胸主动脉直径的决定因素。本研究纳入了2003-2006年2505名(1208名男性,平均年龄69.1±6.8岁)接受了非增强心脏CT检测的参与者,并在肺分叉水平对升主动脉(AA)和降主动脉(DA)的直径进行了测量。分析结果显示,男性的AA和DA直径明显大于女性,男性是更大的DA直径的独立相关因素(β 0.24, 95%

Heart:孤单与心脏病患者不良预后明显相关!

本研究的目的旨在评估孤单是否与缺血性心脏病、心律失常、心衰或心脏瓣膜疾病患者出院后的预后相关。本研究纳入分析了13443名缺血性心脏病、心律失常、心衰或心脏瓣膜疾病患者,并完成了调查随访,其中男性占70%,女性平均年龄是66.1岁,男性的平均年龄是64.9岁。分析结果显示,在不同的疾病种类中,孤单均与更差的预后相关,不论男性和女性。孤单可以预测患者的全因死亡率(男性:HR 2.92,95% CI

JACC:巨噬细胞在心梗后有转化为成纤维细胞的能力

巨噬细胞和成纤维细胞是心梗后愈合的两个主要细胞类型,参与心肌重塑和纤维化过程。本研究的目的旨在评估巨噬细胞表达纤维化基因的潜能和在心梗后心肌纤维化中的直接作用。本研究采用的小鼠模型是LysM(Cre/+);ROSA26(EYFP/+),其中黄色荧光蛋白(YFP)的表达局限在髓系以鉴定巨噬细胞来源的成纤维细胞,结果发现心梗后YFP阳性心脏细胞明显表达纤维化的标志物I型胶原、脯氨酰-4-羟化酶、成纤维

盘点:JACC12月第三期研究一览

1. 颈动脉支架置入术的围手术期预后研究DOI: 10.1016/j.jacc.2019.10.032http://www.onlinejacc.org/content/74/25/3071本研究的目的旨在评估一组颈动脉支架置入术(CAS)治疗无症状和症状性颈动脉狭窄的围手术期结局。本研究纳入分析了无症状颈动脉狭窄≥70%和有症状≥50%的年龄≤80岁的颈动脉狭窄患者,主要终点事件是术后30天

Heart:艾森曼格综合征患者移植术后生存率研究

艾森曼格综合征(ES)患者心脏移植的最佳时间尚不清楚,本研究的目的旨在评估ES患者心肺移植(HLTx)或肺移植(LTx)后的生存率和移植相关死亡率。本研究纳入分析了1985-2012年714名ES患者,其中63名(9%)接受了移植手术。患者接受移植手术时的平均年龄为31.9岁,在移植后的30天内,有7名患者死亡(11%)。平均的生存时间是12年,1年、5年、10年和15年的总体生存率分别为84.1

Heart:心包脂肪含量与HIV患者不良的心功能相关

艾滋病毒携带者(PLHIV)改变了脂肪分布,增加了心力衰竭的风险,在这个人群中,心脏周围脂肪的数量和放射密度的改变是否与心功能不全有关尚不清楚。本研究的目的旨在评估HIV患者的心包脂肪(PCF)与心脏功能的相关性。本研究纳入分析了100例年龄>45岁且存在>1个传统心血管危险因素的HIV患者和100年龄和性别匹配的对照。与对照相比,PLHIV患者的BMI更低(27 vs 30, p=0.02),糖